Esperion Therapeutics
ESPR
ESPR
165 hedge funds and large institutions have $99.3M invested in Esperion Therapeutics in 2025 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 56 increasing their positions, 41 reducing their positions, and 34 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less funds holding
Funds holding: →
42% less capital invested
Capital invested by funds: $171M → $99.3M (-$71.7M)
56% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 34
68% less call options, than puts
Call options by funds: $242K | Put options by funds: $768K
Holders
165
Holding in Top 10
1
Calls
$242K
Puts
$768K
Top Buyers
| 1 | +$4.6M | |
| 2 | +$2.98M | |
| 3 | +$1.65M | |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.14M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$853K |
Top Sellers
| 1 | -$14M | |
| 2 | -$5.44M | |
| 3 | -$2.62M | |
| 4 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$1.54M |
| 5 |
JPMorgan Chase & Co
New York
|
-$1.34M |
